Research Continues Evaluating Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
November 14th 2022Belantamab mafodotin-blmf is a first-in-class, anti-B-cell maturation antigen therapy indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies.
Read More